source
- Gilead’s emvistegrast shows superior response to placebo in Phase 2 ulcerative colitis trialGilead Sciences reported that its investigational oral drug emvistegrast achieved a higher clinical response rate than placebo in a Phase 2 study of ulcerative colitis. The trial enrolled 238 patie…
- Rapport Therapeutics reports Phase 2 success for J&J-licensed bipolar mania drugRapport Therapeutics announced that its oral investigational drug, which modulates AMPA receptors, has successfully completed a Phase 2 trial in patients with bipolar mania. The study met its prim…